SuperNova Diagnostics, Concile Reach European Co-marketing Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Point-of-care firm SuperNova Diagnostics today announced a co-marketing deal with Concile for a test that assesses "various deficiencies" relating to wellness and chronic diseases.

The terms of the deal gives Concile, a German diagnostic development and distribution firm, the rights to co-market SuperNova's test in Europe. SuperNova will develop and manufacture the test, secure regulatory approvals, and co-market it.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.